Trial · NCT04532372
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANEMIA | Blood and lymphatic system disorders | Phase I (Leflunomide, SOC) | 2 | 2 | 2 |
| other | CONSTIPATION | Gastrointestinal disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | DYSPHAGIA | Gastrointestinal disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | FATIGUE | General disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | FEVER | General disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | GENERALIZED EDEMA | General disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | NON-CARDIAC CHEST PAIN | General disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | COVID-19 | Infections and infestations | Phase I (Leflunomide, SOC) | 2 | 2 | 2 |
| other | ALANINE AMINOTRANSFERASE INCREASED | Investigations | Phase I (Leflunomide, SOC) | 1 | 2 | 2 |
| other | ASPARTATE AMINOTRANSFERASE INCREASED | Investigations | Phase I (Leflunomide, SOC) | 1 | 2 | 2 |
| other | BLOOD LACTATE DEHYDROGENASE INCREASED | Investigations | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | LYMPHOCYTE COUNT DECREASED | Investigations | Phase I (Leflunomide, SOC) | 2 | 2 | 3 |
| other | NEUTROPHIL COUNT DECREASED | Investigations | Phase I (Leflunomide, SOC) | 1 | 2 | 2 |
| other | PLATELET COUNT DECREASED | Investigations | Phase I (Leflunomide, SOC) | 2 | 2 | 3 |
| other | WHITE BLOOD CELL DECREASED | Investigations | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | HYPERGLYCEMIA | Metabolism and nutrition disorders | Phase I (Leflunomide, SOC) | 2 | 2 | 3 |
| other | HYPOALBUMINEMIA | Metabolism and nutrition disorders | Phase I (Leflunomide, SOC) | 2 | 2 | 2 |
| other | HYPOCALCEMIA | Metabolism and nutrition disorders | Phase I (Leflunomide, SOC) | 2 | 2 | 2 |
| other | HYPOGLYCEMIA | Metabolism and nutrition disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 1 |
| other | HYPOKALEMIA | Metabolism and nutrition disorders | Phase I (Leflunomide, SOC) | 1 | 2 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04532372/events